LJN452
Total Payments
$8.5M
Transactions
241
Doctors
15
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1.1M | 42 | 2 |
| 2019 | $3.5M | 97 | 7 |
| 2018 | $2.6M | 62 | 2 |
| 2017 | $1.4M | 40 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.5M | 189 | 99.5% |
| Consulting Fee | $36,000 | 12 | 0.4% |
| Travel and Lodging | $5,407 | 21 | 0.1% |
| Food and Beverage | $1,374 | 19 | 0.0% |
Payments by Type
Research
$8.5M
189 transactions
General
$42,781
52 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH | Novartis Pharmaceuticals Corporation | $7.1M | 1 |
| A PHASE 1 OPEN LABEL SINGLE DOSE MULTI CENTER PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF TROPIFEXOR LJN452 IN SUBJECTS WITH MILD MODERATE OR SEVERE HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | Novartis Pharmaceuticals Corporation | $429,475 | 0 |
| AN OPEN LABEL SINGLE CENTER SINGLE DOSE STUDY IN HEALTHY ADULT MALE VOLUNTEERS TO ASSESS THE ABSORPTION METABOLISM AND EXCRETION OF A SINGLE ORAL DOSE OF 1 MG 14C LJN452 | Novartis Pharmaceuticals Corporation | $332,997 | 0 |
| A MULTI PART RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS | Novartis Pharmaceuticals Corporation | $245,177 | 0 |
| A DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED CROSSOVER MULTIPLE DOSE STUDY OF LJN452 TO ASSESS SAFETY TOLERABILITY AND EFFICACY IN PATIENTS WITH PRIMARY BILE ACID DIARRHEA PBAD | Novartis Pharmaceuticals Corporation | $202,671 | 0 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH | NOVARTIS PHARMACEUTICALS CORPORATION | $67,440 | 2 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $24,621 | 0 |
| A PHASE 1 OPEN LABEL SINGLE DOSE MULTI CENTER PARALLEL GROUP STUDY TO EVALUATE THE PHARMACOKINETICS OF TROPIFEXOR LJN452 IN SUBJECTS WITH MILD MODERATE OR SEVERE HEPATIC IMPAIRMENT COMPARED TO HEALTHY CONTROL SUBJECTS | NOVARTIS PHARMACEUTICALS CORPORATION | $12,085 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,875 | 1 |
| A RANDOMIZED, INVESTIGATOR AND SUBJECT BLINDED, MULTICENTER, PARALLEL-ARM STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF TROPIFEXOR | Novartis Pharmaceuticals Corporation | $75.00 | 1 |
Top Doctors Receiving Payments for LJN452
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $8.4M | 182 |
| , MD | Diagnostic Radiology | Rochester, NY | $17,520 | 5 |
| , MD | Infectious Disease | Chandler, AZ | $7,765 | 8 |
| , M.D | Gastroenterology | Cincinnati, OH | $7,760 | 8 |
| , MD | Gastroenterology | Murray, UT | $7,672 | 8 |
| , MD | Gastroenterology | Marietta, GA | $7,645 | 7 |
| Sherwyn Schwartz | Endocrinology, Diabetes & Metabolism | San Antonio, TX | $6,733 | 7 |
| , MD | Internal Medicine | Boston, MA | $5,186 | 8 |
| , MD | Gastroenterology | Chicago, IL | $1,875 | 1 |
| , M.D | Cardiovascular Disease | Rochester, NY | $187.50 | 1 |
| , M.D | Gastroenterology | Dallas, TX | $4.68 | 1 |
| , MD | Hepatology | Plano, TX | $4.68 | 1 |
| , MD | Hepatology | Miami, FL | $2.38 | 1 |
| , MD | Gastroenterology | Boston, MA | $2.38 | 1 |
| , M.D | Gastroenterology | Worcester, MA | $2.38 | 1 |
| , M.D | Hepatology | Coronado, CA | $2.38 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $8.5M
- Total Doctors 15
- Transactions 241
About LJN452
LJN452 is a drug associated with $8.5M in payments to 15 healthcare providers, recorded across 241 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $1.1M was paid across 42 transactions to 2 doctors.
The most common payment nature for LJN452 is "Unspecified" ($8.5M, 99.5% of total).
LJN452 is associated with 10 research studies, including "A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH" ($7.1M).